I agree Supertramp. PWN have several ways they can look at funding projects as well as possible partners and major shareholders who may help. One method often used in the larger projects is progress payments which tends to break the working capital requirements down to much smaller values. The risk vs reward here is definitely improving consistently despite the languishing SP. Also good to see you are still here and on some of those promising biotechs too.
I agree Supertramp. PWN have several ways they can look at...
-
- There are more pages in this discussion • 30 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PWN (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.2¢ |
Change
-0.001(7.69%) |
Mkt cap ! $33.20M | |||
| Open | High | Low | Value | Volume |
| 1.3¢ | 1.3¢ | 1.2¢ | $3.953K | 315.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 1303716 | 1.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.3¢ | 2109262 | 4 |
View Market Depth
| Last trade - 10.37am 11/11/2024 (20 minute delay) ? |
| PWN (ASX) Chart |